热疗联合FOLFOX4方案治疗晚期原发性肝癌的临床观察
| 作者: |
1刘海波,
1曹明,
1胡大勇,
1黄文琴
1 勉县医院肿瘤科，陕西 勉县 724200 |
| 通讯: |
刘海波
Email: lhb0916@sina.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.03.007 |
摘要
目的：探讨热疗联合FOLFOX4方案治疗晚期原发性肝癌患者的疗效、及其不良反应和对生活质量的影响。方法：126例晚期原发性肝癌患者纳入本研究，所有患者给予FOLFOX4方案化疗，具体包括奥沙利铂100 mg/m2静脉滴注第一天，亚叶酸钙200 mg/m2静脉滴注1~5 d，氟尿嘧啶400 mg/m2静脉滴注1~5 d。治疗组在每一周期的化疗期间联合局部区域热疗，每天1次，共5次。对照组给予单纯化疗。每2个周期评价疗效，持续至6周期，或至疾病进展或出现不能耐受的毒性。客观疗效按RECIST标准评价，毒物反应按照美国NCI CTC标准评。结果：治疗组66例患者中完全缓解7例、部分缓解13例、疾病稳定18例，中位生存时间7.2个月。对照组60例患者完全缓解2例、部分缓解6例、疾病稳定14例，中位生存时间6.5个月。两组患者毒性反应主要为粒细胞减少、胃肠道反应和较轻的神经毒性，两组比较无显著性差异。结论：热疗联合FOLFOX4方案治疗晚期原发性肝癌疗效可靠，毒性反应较轻，值得进一步推广。
关键词：
发性肝癌
化学治疗
热疗法
Clinical observation of thermal therapy in combination with FOLFOX4 regimen in primary hepatocarcinoma
CorrespondingAuthor: LIU Haibo Email: lhb0916@sina.com
DOI: 10.3978/j.issn.2095-6959.2016.03.007
Abstract
Objective: To evaluate the efficacy and taxicity of thermal therapy in combination with FOLFOX4 regimen in primary hepatocarcinoma. Methods: A total of 126 patients with advanced primary hepatocarcinoma were treated with L-OHP 100 mg/m2, ivgtt (day 1); CF 200 mg/m2, ivgtt (day 1~5); 5-Fu 400 mg/m2, ivgtt (day 1~5). The patients in treatment group received additional thermal therapy, but control group not. The efficacy and toxicitis were respectively evaluated according to RECIST criteria and NCL CTC. Results: A total of 66 patients were available for the objective efficiency and toxicity, including 7 with complete response (CR), 13 with partial response (PR),
18 with stable disease (SD). The 60 patients were involved in the control group, including 2 with CR, 6 with PR, 14 with SD. The median overall survive was 7.2 months in the treatment group and 6.5 months in control group. The main toxicities were granulocytopenia, nausea, vomiting, and mmild neurotoxicity. Conclusion: The thermal therapy in combination with FOLFOX4 regimen was effective and safe for patients with advanced primary hepatocarcinoma.
18 with stable disease (SD). The 60 patients were involved in the control group, including 2 with CR, 6 with PR, 14 with SD. The median overall survive was 7.2 months in the treatment group and 6.5 months in control group. The main toxicities were granulocytopenia, nausea, vomiting, and mmild neurotoxicity. Conclusion: The thermal therapy in combination with FOLFOX4 regimen was effective and safe for patients with advanced primary hepatocarcinoma.